Bank of New York Mellon
BXRX

Bank of New York Mellon’s Baudax Bio, Inc. Common Stock BXRX Stock Holding History

Bank of New York Mellon’s Portfolio BXRX Stock Details BXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-72
Closed -$131K – 4514
2021
Q1 		$131K Buy
+72
New +$144K ﹤0.01% 4132
2020
Q3 		– Sell
-8
Closed -$49K – 4171
2020
Q2 		$49K Sell
8
-11
-58% -$52.8K ﹤0.01% 3988
2020
Q1 		$66K Hold
19
– – ﹤0.01% 3927
2019
Q4 		$184K Buy
+19
New +$162K ﹤0.01% 3937

Other funds holding BXRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
EDRH
Edmond de Rothschild Holding Chambesy, Switzerland $7.59B AUM 23.44% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Bank of New York Mellon's BXRX Position: Q2 2021 in Review

Bank of New York Mellon sold out of Baudax Bio, Inc. Common Stock (BXRX) in Q2 2021, closing a stake of 72 shares — an estimated $131K sold.

Bank of New York Mellon first reported a position in BXRX in Q4 2019 and held it in 4 quarters. The position peaked at $184K in Q4 2019. 31 funds tracked by Wall St. Rank hold BXRX as of Q2 2021.

  • Bank of New York Mellon reported no remaining Baudax Bio, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Bank of New York Mellon sold 72 Baudax Bio, Inc. Common Stock shares in Q2 2021, an estimated $131K.
  • Bank of New York Mellon first reported a position in Baudax Bio, Inc. Common Stock in Q4 2019 and held it in 4 quarters.
  • Bank of New York Mellon's Baudax Bio, Inc. Common Stock position peaked at $184K in Q4 2019.
  • 31 funds tracked by Wall St. Rank held Baudax Bio, Inc. Common Stock as of Q2 2021.

Based on Bank of New York Mellon's 13F filing for Q2 2021, filed 11 Aug 2021.